amarin corp. plc - AMRN

AMRN

Close Chg Chg %
0.52 0.02 4.52%

Closed Market

0.55

+0.02 (4.52%)

Volume: 1.37M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Company Overview: amarin corp. plc - AMRN

AMRN Key Data

Open

$0.53

Day Range

0.52 - 0.56

52 Week Range

0.46 - 1.37

Market Cap

$213.86M

Shares Outstanding

411.26M

Public Float

409.93M

Beta

1.93

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.10

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.37M

 

AMRN Performance

1 Week
 
9.72%
 
1 Month
 
-5.76%
 
3 Months
 
-12.73%
 
1 Year
 
-29.92%
 
5 Years
 
-97.38%
 

AMRN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About amarin corp. plc - AMRN

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

AMRN At a Glance

Amarin Corp. Plc
Iconic Offices, The Greenway
Dublin, Dublin 2
Phone 353-1-6699-020 Revenue 308.10M
Industry Pharmaceuticals: Major Net Income -59,341,122.34
Sector Health Technology Employees 275
Fiscal Year-end 12 / 2024
View SEC Filings

AMRN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.151
Price to Book Ratio 0.644
Price to Cash Flow Ratio 51.35
Enterprise Value to EBITDA -2.915
Enterprise Value to Sales 0.137
Total Debt to Enterprise Value 0.207

AMRN Efficiency

Revenue/Employee 1,120,365.851
Income Per Employee -215,785.899
Receivables Turnover 2.307
Total Asset Turnover 0.359

AMRN Liquidity

Current Ratio 2.796
Quick Ratio 1.799
Cash Ratio 1.239

AMRN Profitability

Gross Margin 65.753
Operating Margin -5.665
Pretax Margin -17.487
Net Margin -19.26
Return on Assets -6.909
Return on Equity -10.343
Return on Total Capital -10.581
Return on Invested Capital -10.177

AMRN Capital Structure

Total Debt to Total Equity 1.583
Total Debt to Total Capital 1.558
Total Debt to Total Assets 1.051
Long-Term Debt to Equity 1.583
Long-Term Debt to Total Capital 1.558
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amarin Corp. Plc - AMRN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
618.84M 583.12M 368.97M 308.10M
Sales Growth
+43.40% -5.77% -36.73% -16.50%
Cost of Goods Sold (COGS) incl D&A
134.52M 124.17M 129.72M 105.51M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.05M 2.86M 3.09M 2.98M
Depreciation
601.64K 586.93K 550.66K 160.62K
Amortization of Intangibles
1.45M 2.27M 2.54M 2.82M
COGS Growth
+38.28% -7.69% +4.47% -18.66%
Gross Income
484.32M 458.95M 239.24M 202.59M
Gross Income Growth
+44.89% -5.24% -47.87% -15.32%
Gross Profit Margin
+78.26% +78.71% +64.84% +65.75%
2020 2021 2022 2023 5-year trend
SG&A Expense
504.12M 434.73M 331.53M 220.04M
Research & Development
37.21M 26.45M 27.30M 19.33M
Other SG&A
466.92M 408.29M 304.23M 200.71M
SGA Growth
+40.57% -13.76% -23.74% -33.63%
Other Operating Expense
- - - -
-
Unusual Expense
- 13.72M 13.52M 50.39M
EBIT after Unusual Expense
(19.81M) 10.50M (105.80M) (67.85M)
Non Operating Income/Expense
5.04M 917.89K 2.06M 13.97M
Non-Operating Interest Income
4.94M 1.22M 2.82M 11.91M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 2.63M 128.98K
-
Interest Expense Growth
- -60.54% -95.09% -100.00%
Gross Interest Expense
- - 2.63M 128.98K
-
Interest Capitalized
- - - -
-
Pretax Income
(17.39M) 11.29M (103.74M) (53.88M)
Pretax Income Growth
+22.97% +164.92% -1,018.90% +48.06%
Pretax Margin
-2.81% +1.94% -28.12% -17.49%
Income Tax
750.80K 3.56M 2.00M 5.46M
Income Tax - Current - Domestic
45.35K 3.41M 1.13M 1.85M
Income Tax - Current - Foreign
705.45K 155.98K 862.47K 3.62M
Income Tax - Deferred - Domestic
- - 1.64M 15.47M
-
Income Tax - Deferred - Foreign
- - (1.64M) (15.47M)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.14M) 7.73M (105.74M) (59.34M)
Minority Interest Expense
- - - -
-
Net Income
(18.14M) 7.73M (105.74M) (59.34M)
Net Income Growth
+20.22% +142.60% -1,468.23% +43.88%
Net Margin Growth
-2.93% +1.33% -28.66% -19.26%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(18.14M) 7.73M (105.74M) (59.34M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(18.14M) 7.73M (105.74M) (59.34M)
EPS (Basic)
-0.0475 0.0195 -0.2636 -0.1456
EPS (Basic) Growth
+28.46% +141.05% -1,451.79% +44.76%
Basic Shares Outstanding
381.76M 395.99M 401.15M 407.65M
EPS (Diluted)
-0.0475 0.0192 -0.2636 -0.1456
EPS (Diluted) Growth
+28.46% +140.42% -1,472.92% +44.76%
Diluted Shares Outstanding
381.76M 402.48M 401.15M 407.65M
EBITDA
(17.75M) 27.07M (89.19M) (14.48M)
EBITDA Growth
+24.51% +252.49% -429.45% +83.77%
EBITDA Margin
-2.87% +4.64% -24.17% -4.70%

Snapshot

Average Recommendation UNDERWEIGHT Average Target Price 1.00
Number of Ratings 3 Current Quarters Estimate -0.053
FY Report Date 12 / 2024 Current Year's Estimate -0.137
Last Quarter’s Earnings -0.06 Median PE on CY Estimate N/A
Year Ago Earnings -0.15 Next Fiscal Year Estimate -0.21
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 1 3 3
Mean Estimate -0.05 -0.06 -0.14 -0.21
High Estimates -0.04 -0.06 -0.12 -0.16
Low Estimate -0.07 -0.06 -0.16 -0.29
Coefficient of Variance -28.64 N/A -15.23 -33.33

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 1 1
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 2 2 2
MEAN Underweight Underweight Underweight

Insider Actions for Amarin Corp. Plc - AMRN

Date Name Shares Transaction Value
Feb 12, 2024 Steven B. Ketchum Chief Scientific Officer 116,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 12, 2024 Steven B. Ketchum Chief Scientific Officer 418,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 12, 2024 Aaron D. Berg EVP, President US 116,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 12, 2024 Aaron D. Berg EVP, President US 418,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 12, 2024 Thomas Reilly EVP and CFO 116,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 12, 2024 Thomas Reilly EVP and CFO 418,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Amarin Corp. Plc in the News